The Phase III Clinical Trial of X842 Capsules for Reflux Esophagitis
Status:
COMPLETED
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of X842 Capsules 50 mg compared to Lansoprazole Enteric Capsules for the treatment of reflux esophagitis, and to characterize the population pharmacokinetics of X842 capsules in this patient population.